Itonis Inc (ITNS) 0.0072 $ITNS Hensley Brothers

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Itonis Inc (ITNS) 0.0072 $ITNS

Hensley Brothers Distribution, LLC Reveals Cruise Line Distribution Channel For Itonis Holdings? Emesyl Nausea Relief
ACCESSWIRE - Tue Mar 24, 7:58AM CDT
LOS ANGELES, CA / ACCESSWIRE / March 24, 2015 / Hensley Brothers Distribution, LLC., a California based consumer products distribution company distributing a diverse class of consumer products domestically and internationally revealed their cruise line distribution channel for EMESYL Nausea Relief.

Hensley Brothers Distribution Announces Nationwide Rollout For Itonis Holdings' Emesyl Nausea Relief
ACCESSWIRE - Wed Mar 18, 12:22PM CDT
LOS ANGELES, CA / ACCESSWIRE / March 18, 2015 / Hensley Brothers Distribution, LLC, a California based consumer products distribution company distributing a diverse class of consumer products domestically and internationally announced today that they are rolling out EMESYL Nausea Relief nationwide.

53 Marijuana Stocks - A Post-Mortem: Part III And Epilogue
Anthony Cataldo - at Seeking Alpha - Thu Mar 05, 2:25PM CST

VPCO: 1.04 (+0.02)

12 More Marijuana Stocks To Avoid - Part I
Anthony Cataldo - at Seeking Alpha - Thu Feb 19, 6:21AM CST

XXII: 0.86 (-0.02), VPCO: 1.04 (+0.02)

Itonis to Ship More Emesyl(TM) Nausea Relief to Hensley Brothers Distribution, LLC
ACCESSWIRE - Tue Feb 03, 9:30AM CST
LAGUNA HILLS, CA / ACCESSWIRE / February 03, 2015 / Itonis, Inc. (OTC PINKSHEETS: ITNS)

Itonis Delivers First Shipment of its Emesyl(TM) Nausea Relief Product to Hensley Brothers Distribution, Commencing Domestic Retail
ACCESSWIRE - Tue Jan 27, 8:01AM CST
Itonis Delivers First Shipment of its Emesyl(TM) Nausea Relief Product to Hensley Brothers Distribution, Commencing Domestic Retail Sales Distribution

Itonis Pharmaceuticals Announces Completion of Stability Test for Emesyl(R) and Delivery Date of Emesyl(R) with New Packaging Design
ACCESSWIRE - Thu Dec 18, 9:41AM CST
LAGUNA HILLS, CA / ACCESSWIRE / December 18, 2014 / Itonis, Inc. (OTC PINKSHEETS: ITNS) is pleased to announce that it has received confirmation from its manufacturer, Oasis Health Products, that its Emesyl(R) nausea relief product has passed its Stability Test to enable the company to market Emesyl(R) with a 2-year expiration date.

Itonis Pharmaceuticals Announces Emesyl(R) Website on New Nausea Relief Product
ACCESSWIRE - Tue Oct 21, 8:04AM CDT
Image: https://www.baystreet.ca/uploads/Itonis%20Logo.jpg

Itonis Pharmaceuticals Announces First Emesyl(R) Manufacturer Production Release Date
Marketwire - Tue Aug 12, 7:31AM CDT
Itonis, Inc. (PINKSHEETS: ITNS)

Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run
Marketwire - Wed Jun 25, 7:03AM CDT
Itonis, Inc. (PINKSHEETS: ITNS) Itonis is pleased to announce that, with the finalization of its new packaging design and product labeling, it has given the go ahead to Oasis Health Products to produce 16,000 units of its Emesyl(R) homeopathic product. Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run.

Itonis Pharmaceuticals Completes Final Package Design, Enabling Start of Emesyl(R) Production
Marketwire - Thu Jun 19, 9:00AM CDT
Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that the final product packaging and bottle label designs for its Emesyl(R) over-the-counter homeopathic product for nausea relief are now complete. The finalized packaging design includes the 800 product phone number, the product information website, the product UPC code, and a brand new visual look that is very appealing to consumers. New pictures of the final box and bottle designs can be found on the company's website news tab at # http://www.itonisholdings.com/news.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading